HEPATYS - Cohort study on management and outcome of patients with chronic Hepatitis C treated with PEG-IFN-alpha2a in combinaison with ribavirin in hospital-based or private office-based 
Head :
Pinta Alexandrina, ROCHE
Last update : 09/05/2017 | Version : 2 | ID : 177
| General | |
| Identification | |
| Detailed name | Cohort study on management and outcome of patients with chronic Hepatitis C treated with PEG-IFN-alpha2a in combinaison with ribavirin in hospital-based or private office-based |
| Sign or acronym | HEPATYS |
| General Aspects | |
| Medical area |
Gastroenterology et hepatology |
| Keywords | chronic hepatitis C, Pegasys |
| Scientific investigator(s) (Contact) | |
| Name of the director | Pinta |
| Surname | Alexandrina |
| Phone | +33 (0)1 46 40 43 76 |
| alexandrina.pinta@roche.com | |
| Unit | ROCHE |
| Collaborations | |
| Funding | |
| Funding status |
Private |
| Details | Roche |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | ROCHE |
| Organisation status |
Private |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Study databases |
| Study databases (details) |
Longitudinal study (except cohorts) |
| Database recruitment is carried out by an intermediary |
A selection of health care professionals A selection of health institutions and services |
| Database recruitment is is made on the basis of: |
Medication(s) taken |
| Database recruitment is carried out as part of an interventional study |
No |
| Database objective | |
| Main objective | Describe the management and outcome of patients with chronic Hepatitis C treated with PEG-IFN-alpha2a in combinaison with ribavirin in hospital-based or private office-based |
| Inclusion criteria |
Patients suffering from chronic hepatitis C for whom a treatment via Pagasys was decided and then initiated, followed in a hospital and general environment
Patients who have been informed of the study orally and in writing |
| Population type | |
| Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) |
| Population covered |
Sick population |
| Gender |
Male Woman |
| Geography area |
National |
| Detail of the geography area | France |
| Data collection | |
| Dates | |
| Date of first collection (YYYY or MM/YYYY) | 2003 |
| Date of last collection (YYYY or MM/YYYY) | 2006 |
| Size of the database | |
| Size of the database (number of individuals) |
[1000-10 000[ individuals |
| Details of the number of individuals | 2155 |
| Data | |
| Database activity |
Data collection completed |
| Type of data collected |
Clinical data Biological data |
| Clinical data (detail) |
Direct physical measures |
| Biological data (detail) | HCV viral load, Hb, Platelets, Leukocytes, creatinine |
| Presence of a biobank |
No |
| Health parameters studied |
Health event/morbidity Health event/mortality Health care consumption and services Quality of life/health perception |
| Care consumption (detail) |
Hospitalization Medical/paramedical consultation Medicines consumption |
| Procedures | |
| Participant monitoring |
Yes |
| Links to administrative sources |
No |
| Promotion and access | |
| Promotion | |
| Link to the document | http://www.ncbi.nlm.nih.gov/pubmed/?term=Pinta+A[author]+AND+hepatys |
| Description | List of publications in Pubmed |
| Access | |
| Terms of data access (charter for data provision, format of data, availability delay) | Oral and posted communication at the hepatology congress (AFEF (French Association for the study of the liver), AASLD (American Association for the Study of Liver Diseases), JFHOD (French-Speaking Days on Hepato-Gastroenterology and Digestive Oncology)), infectiology (RICAI (Interdisciplinary Meeting on Anti-Infective Chemotherapy)), pharmaco-economics, pharmaco-epidemiology |
| Access to aggregated data |
Access on specific project only |
| Access to individual data |
Access on specific project only |
